Point72 Asset Management Reports 8.4%Passive Stake in Inhibikase Therapeutics as of Oct 9- SEC Filing
Point72資產管理報告截至10月9日的Inhibikase Therapeutics被動持股8.4%-SEC備案
Point72 Asset Management Reports 8.4%Passive Stake in Inhibikase Therapeutics as of Oct 9- SEC Filing
Point72資產管理報告截至10月9日的Inhibikase Therapeutics被動持股8.4%-SEC備案
譯文內容由第三人軟體翻譯。